Mitochondrial integrity in neurodegeneration
dc.contributor.author | Cowan, K | |
dc.contributor.author | Anichtchik, O | |
dc.contributor.author | Luo, S | |
dc.date.accessioned | 2021-10-19T11:24:24Z | |
dc.date.issued | 2019-07 | |
dc.identifier.issn | 1080-563X | |
dc.identifier.issn | 1755-5949 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/18111 | |
dc.description.abstract |
<jats:title>Summary</jats:title><jats:p>The mitochondrion is a unique organelle with a diverse range of functions. Mitochondrial dysfunction is a key pathological process in several neurodegenerative diseases. Mitochondria are mostly important for energy production; however, they also have roles in Ca<jats:sup>2+</jats:sup> homeostasis, ROS production, and apoptosis. There are two major systems in place, which regulate mitochondrial integrity, mitochondrial dynamics, and mitophagy. These two processes remove damaged mitochondria from cells and protect the functional mitochondrial population. These quality control systems often become dysfunctional during neurodegenerative diseases, such as Parkinson's and Alzheimer's disease, causing mitochondrial dysfunction and severe neurological symptoms.</jats:p> | |
dc.format.extent | 825-836 | |
dc.format.medium | Print-Electronic | |
dc.language | en | |
dc.language.iso | en | |
dc.publisher | Wiley | |
dc.subject | cytotoxicity | |
dc.subject | mitochondrion | |
dc.subject | mitophagy | |
dc.subject | neurodegeneration | |
dc.title | Mitochondrial integrity in neurodegeneration | |
dc.type | journal-article | |
dc.type | Review | |
plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/30746905 | |
plymouth.issue | 7 | |
plymouth.volume | 25 | |
plymouth.publication-status | Published | |
plymouth.journal | CNS Neuroscience and Therapeutics | |
dc.identifier.doi | 10.1111/cns.13105 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
plymouth.organisational-group | /Plymouth/Users by role/Researchers in ResearchFish submission | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2018-12-25 | |
dc.rights.embargodate | 2021-10-20 | |
dc.identifier.eissn | 1755-5949 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1111/cns.13105 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2019-07 | |
rioxxterms.type | Journal Article/Review | |
plymouth.funder | Tackling autophagy and apoptosis for the potential therapy of Huntington's Disease::MRC |